Bayer (BAYN.DE) — Upcoming Catalysts

FDA PDUFA dates, advisory-committee meetings, and Phase 2/3 readout windows for Bayer, built from public data lanes (ClinicalTrials.gov and official sources). Each row links to its source.

For informational purposes only — not investment advice. Track BAYN.DE live on Mooboard →

Next 30 days1

  • Aug 31, 2026
    Bayer(BAYN.DE)Phase 2/3 readout
    BAY3723113 · Phase 3 · Obstructive Hypertrophic Cardiomyopathy
    NCT07023341: A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy. Primary completion 2026-08-31 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗

31–90 days1

  • Sep 15, 2026
    Bayer(BAYN.DE)Phase 2/3 readout
    BAY2599023 (DTX201) · Phase 1 / Phase 2 · Hemophilia A
    NCT03588299: Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle". Primary completion 2026-09-15 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗

Later14

  • Feb 3, 2027
    Bayer(BAYN.DE)Phase 2/3 readout
    BAY2927088 · Phase 2 · Advanced Solid Tumors; HER2 Mutation
    NCT06760819: A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2). Primary completion 2027-02-03 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • May 31, 2027
    Bayer(BAYN.DE)Phase 2/3 readout
    Finerenone (Kerendia, BAY94-8862) · Phase 3 · Chronic Kidney Disease; Proteinuria
    NCT05196035: A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria. Primary completion 2027-05-31 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jul 30, 2027
    Bayer(BAYN.DE)Phase 2/3 readout
    Darolutamide (BAY1841788, Nubeqa) · Phase 3 · Biochemically Recurrent Prostate Cancer
    NCT05794906: A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies. Primary completion 2027-07-30 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Oct 28, 2027
    Bayer(BAYN.DE)Phase 2/3 readout
    Sevabertinib · Phase 3 · Advanced Non-small Cell Lung Cancer, HER2 Mutation
    NCT06452277: A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2). Primary completion 2027-10-28 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Apr 27, 2028
    Bayer(BAYN.DE)Phase 2/3 readout
    Regorafenib (Stivarga, BAY73-4506) · Phase 2 · Solid Malignant Tumors
    NCT06246643: A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies. Primary completion 2028-04-27 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 15, 2028
    Bayer(BAYN.DE)Phase 2/3 readout
    Darolutamide · Phase 2 · High-Risk Localized Prostate Cancer
    NCT07450599: A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.. Primary completion 2028-06-15 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 26, 2028
    Bayer(BAYN.DE)Phase 2/3 readout
    Darolutamide (Nubeqa, BAY1841788) · Phase 3 · Cancer
    NCT04464226: Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer. Primary completion 2028-06-26 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Jul 27, 2028
    Bayer(BAYN.DE)Phase 2/3 readout
    BAY 3401016 · Phase 2 · Alport Syndrome
    NCT07211685: A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome. Primary completion 2028-07-27 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Nov 28, 2028
    Bayer(BAYN.DE)Phase 2/3 readout
    Finerenone (Kerendia, BAY94-8862) · Phase 3 · Chronic Kidney Disease; Proteinuria
    NCT05457283: A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria. Primary completion 2028-11-28 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 15, 2029
    Bayer(BAYN.DE)Phase 2/3 readout
    AB-1005 · Phase 2 · Parkinson Disease
    NCT07566429: A Study of AB-1005 Gene Therapy in Japanese Adults With Moderate Parkinson's Disease (J-REGENERATE-PD). Primary completion 2029-06-15 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 17, 2029
    Bayer(BAYN.DE)Phase 2/3 readout
    BAY 3713372 · Phase 1 / Phase 2 · MTAP-deleted Solid Tumors
    NCT06914128: A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors. Primary completion 2029-06-17 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Nov 30, 2029
    Bayer(BAYN.DE)Phase 2/3 readout
    Finerenone (Kerendia, BAY94-8862) · Phase 3 · Left Ventricular Systolic Dysfunction; Heart Failure (Pediatric)
    NCT07188805: A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction. Primary completion 2029-11-30 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • May 16, 2030
    Bayer(BAYN.DE)Phase 2/3 readout
    BAY 3670549 · Phase 2 · Atrial Fibrillation
    NCT07625215: A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation. Primary completion 2030-05-16 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 30, 2030
    Bayer(BAYN.DE)Phase 2/3 readout
    Finerenone (Kerendia, BAY94-8862) · Phase 3 · Left Ventricular Systolic Dysfunction; Heart Failure (Pediatric)
    NCT07192952: A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction. Primary completion 2030-12-30 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗

How Bayer has moved — past-year price reactions

How binary is BAYN.DE? Its typical daily move, how often it swings ±10%, and its biggest single-day moves over the last year — useful context for sizing around a catalyst.

1.3%
typical day (1Y)
3
±10% days
42.4%
annualized vol
253
trading days
Largest single-day moves
  • +18.7%2026-06-25no matched headline
  • +12.1%2025-12-02no matched headline
  • +10.9%2025-11-24no matched headline
  • +8.9%2026-07-02no matched headline
  • +7.3%2026-02-17no matched headline
  • -7.1%2026-02-18no matched headline

Real daily price moves over the past year — not every move is a catalyst, and headlines (where shown) are a possible same-day driver, not confirmed causation.

Bayer — active clinical pipeline

Bayer's registered Phase 1–3 programs by asset and indication, derived from ClinicalTrials.gov.

31 assets34 programsPh1 12Ph2 11Ph3 8· 3 post-marketing (Ph4)
AreasOncologyNeuroscienceCardiovascularInfectiousRare / GeneticOther
Darolutamide (BAY1841788, Nubeqa)Oncology · AR
Phase 2
Metastatic Hormone-sensitive Prostate Cancer
Phase 3
Biochemically Recurrent Prostate Cancer
Finerenone (Kerendia, BAY94-8862)Other · NR3C2
Phase 3
Chronic Kidney Disease (2)Left Ventricular Systolic Dysfunction (2)
BAY3723113Cardiovascular
Phase 3
Obstructive Hypertrophic Cardiomyopathy
Darolutamide (Nubeqa, BAY1841788)Oncology · AR
Phase 3
Cancer
Elinzanetant (BAY3427080)Oncology · TACR1/3
Phase 3
Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer
Riociguat (Adempas, BAY63-2521)Cardiovascular · GUCY1B1
Phase 3
Hypertension, Pulmonary
SevabertinibOncology
Phase 3
Advanced Non-small Cell Lung Cancer, HER2 Mutation
AB-1005Neuroscience
Phase 2
Parkinson Disease
BAY 3401016Other
Phase 2
Alport Syndrome
BAY 3670549Cardiovascular
Phase 2
Atrial Fibrillation
BAY 3713372Oncology
Phase 2
MTAP-deleted Solid Tumors
BAY2599023 (DTX201)Rare / Genetic
Phase 2
Hemophilia A
BAY2927088Oncology
Phase 2
Advanced Solid Tumors
BAY2927088_formulation AOncology
Phase 2
Advanced Non-small Cell Lung Cancer
DarolutamideOncology · AR
Phase 2
High-Risk Localized Prostate Cancer
Larotrectinib (Vitrakvi, BAY2757556)Oncology · TRK
Phase 2
Solid Tumors Harboring NTRK Fusion
Regorafenib (Stivarga, BAY73-4506)Oncology · ABL1/RAF1/KIT/FGFR1/MAPK11/FGFR2/FRK/DDR2/BRAF/TEK/PDGFRβ/VEGFR1/RET/EPHA2/TRK
Phase 2
Solid Malignant Tumors
225Ac-PSMA-Trillium (BAY3563254)Oncology
Phase 1
Advanced Metastatic Castration-resistant Prostate Cancer
AspirinOther · PTGS2
Phase 1
Drug-drug Interaction
BAY 3547926Oncology
Phase 1
Hepatocellular Carcinoma
BAY 3771249Oncology
Phase 1
Advanced/Metastatic Colorectal Adenocarcinoma
BAY2965501Oncology
Phase 1
Advanced Solid Tumors
BAY3375968Oncology
Phase 1
Advanced Solid Tumors
BAY3389934Infectious
Phase 1
Sepsis
BAY3498264Oncology
Phase 1
Advanced Solid Tumors Harboring KRAS G12C Mutation
BAY3546828Oncology
Phase 1
Metastatic Castration-resistant Prostate Cancer
MetforminOther
Phase 1
Healthy volunteers
Nitroglycerin sprayCardiovascular
Phase 1
Stable Coronary Artery Disease
Nurandociguat (BAY3283142) old tablet - SDOther
Phase 1
Chronic Kidney Disease

Active registered Phase 1–3 trials from ClinicalTrials.gov — not the company's official IR pipeline (no preclinical or undisclosed assets). Grouped by trial intervention name; therapeutic area is auto-categorized. Each indication links to its trial. Molecular targets sourced from ChEMBL (EMBL-EBI).

See the full biopharma catalyst calendar across all covered companies.